about
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineCombination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysisEfficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patientsHepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, IranMolecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic ReviewHow can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level?Interferon alpha-2b therapy in chronic hepatitis deltaCan serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C.Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study.Interferon-λ Genetic Variations and Hepatitis C: Yet to be Discovered.Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization.Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients.Corrigendum to: Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients [Published in Jundishapur Journal of Microbiology. 2015 March; 8(3): e21444].What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52].Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment.Association of PNPLA3 rs738409 polymorphism with Liver Steatosis but not with Cirrhosis in Patients with HBV Infection: Systematic Review with Meta-analysis.The high-diagnostic characteristics of HBsAg level in differentiation of hepatitis B clinical presentations: Myth or truth?Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.Differentiation of hepatitis B/hepatitis D coinfection and superinfection in asymptomatic blood donors: is it possible?A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms.Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBankSeroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-AnalysisAssociation of -24CT, 1249GA, and 3972CT ABCC2 Gene Polymorphisms with Methotrexate Serum Levels and Toxic Side Effects in Children with Acute Lymphoblastic LeukemiaCan we include genetic variants with high linkage disequilibrium into a multiple logistic model?How Can the IL28B Polymorphisms with Linkage Disequilibrium Affect the Natural Course of Hepatitis B Inversely?Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review
P50
Q28076883-7801EC0B-9D36-4FCA-ADC4-060A6C8D1760Q33582596-AFEC66F9-E9EE-4E77-B8E6-584860ACC28BQ35131583-8A159798-A13C-494A-9A61-57F81B597C45Q35925546-7DCBB9E5-405B-4B16-BF4B-2A1E9E0E3125Q36805354-6B60240F-0C37-42D3-817C-A034B2D2384FQ37587065-D71D35F1-2392-42CE-AF15-768AA2BD6E16Q37631709-CB8774F3-31F4-4BC1-81FF-17CF0E27C5EAQ37707363-DD369A85-F29C-44D3-A145-3AC8609E25C8Q39425219-56A77D63-073D-4D57-B346-6BBB71AB00F2Q40383532-108D3638-3386-441C-81DA-78FD8C44BBE1Q40508435-2614C45E-1821-418E-9C87-B137A5F1CE69Q40824296-F248D769-7D4D-4322-9028-E138B49D91B4Q41203229-E97A8CD8-0141-48B2-AB8B-4EAE7EF46089Q41591618-276D9E95-51B3-4D28-B8B7-94FF6C2F82C5Q42199922-28C20D18-8237-4678-BC15-E5902A9350C5Q42559078-FC0FF77B-1B69-4BD2-B8D5-9457AE44FE96Q42650021-4229CA35-A466-4F63-BBB2-015574A7EC1EQ43534365-B3C24B5C-04BD-4A0F-8298-CD73E36A42B7Q45865339-913E4400-44C1-41E2-95E4-B680237C995DQ47345974-981817BC-6EE4-4204-8037-C63C05D2C02CQ48325034-982145D8-A075-40B3-A7BD-9A919A73658BQ50545974-7B252790-8234-4B5E-8E93-228C417C384FQ51799465-660453A4-A4C8-4DD4-A7FB-56CC0A415B42Q54234971-3CCFBE42-06DF-45F1-8922-D3128A8B293FQ57491238-3FFB2F1E-80A2-4B7C-BDA8-95128E1FD77EQ58564271-60C2F1DD-DC10-456C-8C58-1EF212829151Q58924207-38907E52-C831-4A8C-9DBE-A55E8B93534DQ58924217-3130E4A1-3D32-4999-A592-4D4FD1AD2275Q58924218-72CC57F1-04B0-4DB5-8356-B8A46BBE2950Q58924220-8B673951-4452-4ABC-AC86-C7E599E18795Q91543635-9A1D66B3-A083-49E4-A5FD-0C9DB30B0130
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Heidar Sharafi
@ast
Heidar Sharafi
@en
Heidar Sharafi
@es
Heidar Sharafi
@nl
Heidar Sharafi
@sl
type
label
Heidar Sharafi
@ast
Heidar Sharafi
@en
Heidar Sharafi
@es
Heidar Sharafi
@nl
Heidar Sharafi
@sl
prefLabel
Heidar Sharafi
@ast
Heidar Sharafi
@en
Heidar Sharafi
@es
Heidar Sharafi
@nl
Heidar Sharafi
@sl
P106
P1153
54894153700
P31
P496
0000-0001-9177-9117